No Data
No Data
3D MEDICINES: Annual Report 2024
Express News | Trump stated that the USA will impose tariffs on pharmaceuticals.
Investors who bought high-level pharmaceutical Funds have hope! More than 80% of products achieved positive returns in the first quarter, and recovering losses is promising.
① A total of 264 medical Funds had positive returns in the first quarter of this year, accounting for over 80%, with many Funds achieving returns exceeding 15% this year. ② The net value of medical Funds established in 2020 and 2021 is currently being repaired, and investors who entered at high levels are expected to break even.
3D Medicines' 2024 Loss Narrows, Revenue Drops 30%
In the "Performance" report, 3D MEDICINES (01244.HK) recorded a full-year loss narrowed to 0.183 billion yuan.
3D MEDICINES (01244.HK) announced its full-year results for the year ending last December, with revenue of 0.446 billion yuan (RMB), a year-on-year decrease of 29.8%. The loss narrowed to 0.183 billion yuan, compared to a loss of 0.525 billion yuan in the same period last year; the loss per share was 0.75 yuan. No dividend was declared.
3D MEDICINES (01244) released its annual performance, achieving revenue of 0.446 billion yuan, with sales in the second half of the year increasing by 15.9% compared to the first half.
3D MEDICINES (01244) released its annual performance results for the year ending December 31, 2024, achieving revenue...